Shares in Nemaura Medical (NSDQ:NMRD) jumped today after the company touted positive data from the European clinical trial program for its non-invasive sugarBeat glucose monitoring system.
The summary results were taken from a 25-patient group in the three-stage trial, made up of 80% Type I diabetics and 20% Type II diabetics. Each patient continuously wore the sugarBeat device for 14 hours across seven consecutive days.
Get the full story at our sister site, Drug Delivery Business News.
The post Nemaura Medical touts clinical trial data for non-invasive glucose monitor appeared first on MassDevice.
from MassDevice http://ift.tt/2Gwi5jI
Cap comentari:
Publica un comentari a l'entrada